|
Olverembatinib Clinical Trials
11 actively recruiting trials across 2 locations
▲ +1 trial since May 2026
Also known as: 6-MP, Cytarabine, Daunorubicin, Dexamethasone, Methotrexate +5 more
Pipeline
Phase 2: 3Phase 3: 4Phase 1/2: 1
Top Sponsors
- Ascentage Pharma Group Inc.4
- Institute of Hematology & Blood Diseases Hospital, China3
- The First Affiliated Hospital of Soochow University1
- Peking University People's Hospital1
- M.D. Anderson Cancer Center1
Indications
- Cancer11
- Chronic Myeloid Leukemia3
- Ph-Like1
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive1
- Ph+ ALL1
Other8 trials
Houston, Texas2 trials
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
MD Anderson Cancer Center
Phase 2
Study of Olverembatinib (HQP1351) in Patients With CP-CML
MD Anderson Cancer Center
Phase 3
Birmingham, Alabama1 trial
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ascentage Investigative Site #1044
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.